Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P970003/S253

VNS Therapy System

LivaNova USA, Inc. · Decision date Mar 4, 2026

FDA DECISIONP970003/S253

What did the FDA decide?

FDA records P970003/S253 as a supplement to PMA P970003, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 4, 2026.

FDA approval order statement

approval to utilize an alternate sterilizer to sterilize all VNS devices and products
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Neurology
Decision date
Mar 4, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P970003/S253
Regulatory pathway
PMA supplement
Product code
LYJ
Decision code
OK30
Decision date
Mar 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, autonomic nerve, implanted for epilepsy.

Product code
LYJ
FDA device class
3

For the original device and its historical approval scope, see PMA P970003. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P970003 · Original PMA

    VNS THERAPY SYSTEM

  2. P970003/S251 · Related supplement

    VNS Therapy Model 3100 Programmer, VNS Therapy Model 2000 Programming Wand

  3. P970003/S253 received

    Application receipt date recorded by FDA.

  4. P970003/S253 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P970003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P970003

Product / regulatory recordCompanyPathwayDecision dateSource
LivaNova USA, Inc.PMA approvalJul 16, 1997FDA
VNS Therapy SystemP970003/S248
LivaNova USA, Inc.PMA supplementSep 5, 2025FDA
VNS Therapy SystemP970003/S250
LivaNova USA, Inc.PMA supplementSep 12, 2025FDA
LivaNova USA, Inc.PMA supplementNov 25, 2025FDA
VNS THERAPY SYSTEMP970003/S252
LivaNova USA, Inc.PMA supplementDec 17, 2025FDA
VNS Therapy SystemP970003/S249
LivaNova USA, Inc.PMA supplementAug 12, 2026FDA
VNS Therapy SystemP970003/S254
LivaNova USA, Inc.PMA supplementOct 2, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

LivaNova USA, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
100 Cyberonics Blvd., Houston, TX, 77058

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records